Safety and immunogenicity of concomitant quadrivalent meningococcus ACYW-TT and meningococcus group B vaccines.
Monica A McArthur, Adam Finn, Lawrence Barnes, Richard Burkimsher, Katrina Cathie, Eva Galiza, Paul Heaton, Nicholas Jacobsen, Stephen Jones, Sian Ludman, Patrick Moore, Clare Murray, Daniel Owens, Alexander Trotman, Ray Borrow, Julie Chaix, Arlette Delgado, Estelle Dubois, Youjun Huang, Olga Syrkina, Betzana Zambrano, Mandeep Singh Dhingra, Christine Rehm
NPJ Vaccines 10.1038/s41541-026-01508-7
摘要
摘要
Infants are vulnerable to meningococcal disease. In this open-label phase III study (NCT03632720; registered 13/8/2018), infants were randomised to quadrivalent ACWY conjugated vaccine, MenACYW-TT, at 3 and 12-13 months and four-component meningococcus group B vaccine (4CMenB) at 2, 4, and 12-13 months (Group 1), MenACYW-TT at 3 and 12-13 months and 4CMenB at 2 and 4 months (Group 2), or 4CMenB at 2, 4, and 12-13 months (Group 3). Routine vaccines were also administered per UK schedule. Primary outcome of non-inferiority of seroprotection rates against the four capsular groups (A, C, W, and Y) in Group 1 versus Group 2 at day 30 after the second vaccine dose was demonstrated with seroprotection rates ≥99% against all capsular groups in both groups. In Group 3, cross-reactivity was observed, with hSBA titres against capsular groups A and C increasing >10-fold after the third 4CMenB dose. Reactogenicity was consistent with the known profiles of both vaccines; one case of anaphylaxis related to MenACYW-TT was reported and resolved without sequelae. No new safety concerns were identified.
KM 提取结果
0 个 Figure · 0 个 KM 面板